Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $359.29M
• Dividend Yield: N/A
• Average Volume (3M): 2.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -14.16%
• EPS Growth: 25.80%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 266,141,420
• 10 Day Avg. Volume: 2,505,256
• 30 Day Avg. Volume: 2,307,460
• PEG Ratio: -0.06
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.46
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 3.79
• Enterprise Value/Gross Profit: -24.29
• Enterprise Value/Ebitda: -0.26
• 1Y Price Target: $8.00
• Price Target Upside: 492.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Autolus Therapeutics is experiencing strong revenue growth and strategic geographic expansion, notably with AUCATZYL. However, the financial performance indicates significant profitability and cash flow challenges. Technical indicators suggest caution, and while corporate events bolster future prospects, financial sustainability issues and a negative P/E ratio weigh heavily on the stock's overall score.

Positive Factors

Market Expansion

Strong growth in 2025 is expected as the company aims to expand to 60 target centers, covering about 90% of the target population.

Regulatory Approval

Autolus announced that Aucatzyl (obe-cel) has received MHRA conditional approval in the U.K. for adult patients with r/r ALL.

Sales Performance

Autolus reported an impressive $9.0 million in sales for Aucatzyl in the first quarter, substantially beating our estimate of $2.9 million.

Negative Factors

Regulatory Uncertainty

Receiving a positive NICE opinion will be important for achieving widespread payor coverage.

Stock Volatility

Autolus shares have been volatile following the update, currently down about 6%, but this is viewed as short-term trading dynamics.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Autolus Therapeutics makes money primarily through the development and potential commercialization of its pipeline of programmed T cell therapies. The company's revenue streams include partnerships and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on the sales of successfully developed products. Additionally, Autolus may generate income through licensing agreements, allowing other companies to utilize its proprietary technology for a fee. The company's earnings are significantly influenced by the progress and success of its clinical trials, regulatory approvals, and the competitive landscape within the biopharmaceutical industry.

Autolus Therapeutics Financial Statement Overview

Summary

Autolus Therapeutics is experiencing revenue growth but faces significant challenges with profitability and cash flow management. The company has a strong cash reserve and low leverage but is struggling with negative profit margins and operational losses.

Income Statement

Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.

Balance Sheet

The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.

Cash Flow

Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.12M	1.70M	6.19M	2.33M	242.00K
	Gross Profit
-1.27M	-4.87M	-131.03M	-126.32M	-134.65M
	EBIT
-241.43M	-195.03M	-163.78M	-164.21M	-168.15M
	EBITDA
-182.42M	-156.77M	-135.54M	-132.01M	-160.51M
	Net Income Common Stockholders
-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
588.02M	239.57M	382.44M	310.34M	153.30M
	Total Assets
782.73M	375.38M	490.27M	405.56M	294.24M
	Total Debt
52.63M	52.97M	24.26M	21.00M	54.16M
	Net Debt
-174.75M	-186.60M	-358.18M	-289.34M	-99.14M
	Total Liabilities
355.40M	263.91M	191.60M	92.24M	84.20M
	Stockholders Equity
427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow		Free Cash Flow
-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
	Operating Cash Flow
-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
	Investing Cash Flow
-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
	Financing Cash Flow
589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Negative. The current price of 1.35 is below the 20-day moving average (MA) of 1.37, below the 50-day MA of 1.55, and below the 200-day MA of 2.82, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.27 is Neutral, neither overbought nor oversold. The STOCH value of 57.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALT	59 Neutral	$430.51M	―	-59.86%	―	-95.31%	18.58%
Sector *	52 Neutral	$5.21B	3.49	-43.30%	2.83%	14.70%	-0.24%
AUTL	45 Neutral	$359.29M	―	-49.97%	―	-14.16%	25.80%
TRML	45 Neutral	$387.90M	―	-26.14%	―	―	74.59%
RAPP	44 Neutral	$374.10M	―	-33.14%	―	―	―
CELC	44 Neutral	$403.94M	―	-87.54%	―	―	-4.14%
ABSI	43 Neutral	$350.76M	―	-58.04%	―	-20.71%	22.25%

Autolus Therapeutics Corporate Events

Autolus Therapeutics Reports Q1 2025 Financial Results

Autolus Therapeutics reported its financial results for the first quarter of 2025, highlighting a net product revenue of $9.0 million from AUCATZYL® and securing marketing authorization from the U.K.’s MHRA. The company is advancing its clinical trials, including a Phase 2 trial for lupus nephritis and a Phase 1 trial for multiple sclerosis, with plans to dose the first patients by the end of 2025. Despite a net loss of $70.2 million for the quarter, Autolus remains well-capitalized to support its ongoing and planned clinical developments, aiming to expand its therapeutic reach and address significant unmet medical needs.

Spark’s Take on AUTL Stock

According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.

Autolus Therapeutics receives a low overall score due to financial struggles despite revenue growth. Technical indicators show limited upside, and valuation remains unattractive with negative earnings. The earnings call highlighted strategic achievements and a solid cash position, but financial challenges persist.

To see Spark’s full report on AUTL stock, click here.

Autolus Therapeutics to Present R&D Update April 23

On April 23, 2025, Autolus Therapeutics will present a corporate update at an R&D investor event, which will be accessible via a live webcast and archived on the company’s website. This presentation may impact the company’s operations and industry positioning by providing stakeholders with insights into its ongoing research and development efforts.

Spark’s Take on AUTL Stock

According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.

Autolus Therapeutics faces significant financial challenges, with ongoing losses and negative cash flow impacting its performance. Despite strong cash reserves and a successful product launch, the stock’s technical indicators and valuation show weaknesses. The positive earnings call sentiment partially offsets these issues, but strategic improvements are needed for sustainable growth.

To see Spark’s full report on AUTL stock, click here.

Autolus Therapeutics Announces Leadership Transition in Finance

On February 24, 2025, Autolus Therapeutics announced the resignation of Andrew Mercieca, Vice President of Finance and principal accounting officer, effective August 2025. His departure is amicable and not due to any disagreements with the company. On April 3, 2025, the Board appointed Rob Dolski, the current CFO, as the new principal accounting officer, consolidating his roles without additional compensation, indicating a seamless transition in leadership.

Autolus Therapeutics Launches AUCATZYL® in U.S. Market

Autolus Therapeutics reported its financial results for the year ended December 31, 2024, highlighting significant achievements such as the FDA approval and U.S. commercial launch of AUCATZYL® for adult B-cell acute lymphoblastic leukemia. The company has authorized 33 treatment centers as of March 19, 2025, and aims to expand further in the U.S. and new markets while advancing its clinical pipeline. Autolus also anticipates regulatory decisions in the EU and UK for obe-cel and is progressing with trials in autoimmune diseases. Financially, the company ended 2024 with increased cash reserves, driven by a strategic collaboration with BioNTech, despite reporting a net loss of $220.7 million.